BTIG Research initiated coverage on shares of Cullinan Oncology (NASDAQ:CGEM – Get Rating) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating on the stock.
Cullinan Oncology Stock Performance
Shares of Cullinan Oncology stock opened at $13.41 on Monday. The firm has a fifty day moving average of $12.58 and a two-hundred day moving average of $12.73. The stock has a market capitalization of $611.63 million, a price-to-earnings ratio of 6.04 and a beta of -0.09. Cullinan Oncology has a 52 week low of $7.30 and a 52 week high of $19.21.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.43. As a group, research analysts forecast that Cullinan Oncology will post -3.67 EPS for the current fiscal year.
Insider Activity at Cullinan Oncology
Hedge Funds Weigh In On Cullinan Oncology
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rock Springs Capital Management LP boosted its stake in Cullinan Oncology by 1.0% in the 1st quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company’s stock worth $6,832,000 after purchasing an additional 6,500 shares during the period. Rubric Capital Management LP boosted its stake in shares of Cullinan Oncology by 88.2% during the 3rd quarter. Rubric Capital Management LP now owns 559,737 shares of the company’s stock worth $7,176,000 after buying an additional 262,390 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Cullinan Oncology during the 3rd quarter worth about $538,000. Nisa Investment Advisors LLC boosted its stake in shares of Cullinan Oncology by 24.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company’s stock worth $222,000 after buying an additional 3,341 shares during the last quarter. Finally, Silverarc Capital Management LLC boosted its stake in shares of Cullinan Oncology by 5.4% during the 3rd quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company’s stock worth $2,879,000 after buying an additional 11,465 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
About Cullinan Oncology
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.